0.629
전일 마감가:
$0.493
열려 있는:
$0.62
하루 거래량:
1.41M
Relative Volume:
12.00
시가총액:
$12.32M
수익:
-
순이익/손실:
$-26.56M
주가수익비율:
-0.9677
EPS:
-0.65
순현금흐름:
$-22.29M
1주 성능:
+20.91%
1개월 성능:
+0.75%
6개월 성능:
-35.01%
1년 성능:
-83.63%
BiomX Inc Stock (PHGE) Company Profile
명칭
BiomX Inc
전화
972 7 23942377
주소
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PHGE
BiomX Inc
|
0.629 | 12.32M | 0 | -26.56M | -22.29M | -0.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-04-15 | 개시 | Ladenburg Thalmann | Buy |
BiomX Inc 주식(PHGE)의 최신 뉴스
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com Australia
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
Critical Audit Alert: BiomX Receives Going Concern OpinionWhat This Means - Stock Titan
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan
Phage Therapy Market Know the Scope and Trends - openPR
BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World
BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus
BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
Earnings Scheduled For March 25, 2025 - Benzinga
BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire
BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
BiomX’s $12 Million Financing - Global Legal Chronicle
BiomX Inc. secures $12 million from recent offerings - Investing.com India
Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today
BiomX Announces $12M Funding for BX004 Study - TipRanks
BiomX announces series of financings for aggregate gross proceeds of $12M - MSN
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire
Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan
BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World
Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
Barclays PLC Sells 225,000 Shares of BiomX Inc. (NYSEMKT:PHGE) - Defense World
HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE) - Defense World
BiomX (NYSEMKT:PHGE) Stock Price Down 1.3% – Here’s Why - Defense World
BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World
BiomX regains NYSE compliance - Investing.com
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards - The Manila Times
BiomX Regains NYSE American Listing Compliance After Meeting All Standards - StockTitan
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 12.2% – Should You Sell? - Defense World
BiomX (PHGE) 5-Day RSI : 13.43 (As of Nov. 20, 2024) - GuruFocus.com
BiomX Announces Third Quarter 2024 Financial Results and Clinical Program Updates - Defense World
BiomX Inc (PHGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):